Vector-borne disease
MONDO:0100120An infectious disease where a pathogen is carried and transmitted by another organism that acts as disease vector.
Also known as: vector-borne infection, vector-borne infectious disease
448 clinical trials for this condition and its sub-types, 9 tagged with Vector-borne disease itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Vector-borne disease
-
Malaria 134 trials · 169 incl. sub-types
7 sub-types
- Plasmodium falciparum malaria 78 trials
- Plasmodium vivax malaria 27 trials
- Cerebral malaria 2 trials
- Mixed malaria 1 trial
- Plasmodium malariae malaria 0 trials
- Plasmodium ovale malaria 0 trials
- Blackwater fever 0 trials
-
Dengue disease 74 trials
2 sub-types
- Dengue hemorrhagic fever 7 trials Sub-types →
- Asymptomatic dengue 0 trials
-
Tick-borne infectious disease 9 trials · 41 incl. sub-types
10 sub-types
- Lyme disease 30 trials
- Tick-borne encephalitis 6 trials
- Ehrlichiosis 1 trial Sub-types →
- Human granulocytic anaplasmosis 1 trial
- Borrelia miyamotoi disease 0 trials
- Omsk hemorrhagic fever 0 trials
- Powassan encephalitis 0 trials
- Queensland tick typhus 0 trials
- Rickettsia helvetica spotted fever 0 trials
- Tick-borne relapsing fever 0 trials
-
Chikungunya 31 trials
-
Leishmaniasis 8 trials · 27 incl. sub-types
3 sub-types
- Cutaneous leishmaniasis 14 trials Sub-types →
- Visceral leishmaniasis 14 trials
- Mucocutaneous leishmaniasis 3 trials
-
Mycobacterium avium complex disease 22 trials
-
Schistosomiasis 15 trials · 17 incl. sub-types
7 sub-types
- Schistosoma mansoni infectious disease 4 trials
- Urinary schistosomiasis 3 trials
- Schistosoma japonicum infectious disease 1 trial
- Schistosoma intercalatum infectious disease 0 trials
- Cercarial dermatitis 0 trials
- Intestinal schistosomiasis 0 trials
- Neuroschistosomiasis 0 trials
-
Yellow fever 16 trials
-
Zika virus infectious disease 15 trials
-
Chagas disease 12 trials
-
Filarial elephantiasis 9 trials
-
Onchocerciasis 9 trials
1 sub-type
- Ocular onchocerciasis 2 trials
-
Arbovirus infection 8 trials
-
Lassa fever 6 trials
-
Crimean-Congo hemorrhagic fever 5 trials
-
Mosquito-borne viral encephalitis 0 trials · 5 incl. sub-types
5 sub-types
- Japanese encephalitis 4 trials
- West-Nile encephalitis 1 trial Sub-types →
- La Crosse encephalitis 0 trials
- St. Louis encephalitis 0 trials
- Western equine encephalitis 0 trials
-
Listeriosis 4 trials
1 sub-type
- Listeria meningitis 0 trials
-
Plague 2 trials · 4 incl. sub-types
3 sub-types
- Pneumonic plague 3 trials
- Bubonic plague 1 trial
- Septicemic plague 0 trials
-
Q fever 3 trials
-
Rift valley fever 3 trials
-
Human African trypanosomiasis 2 trials · 3 incl. sub-types
2 sub-types
- Infection by Trypanosoma gambiense 3 trials
- Infection by Trypanosoma rhodesiense 0 trials
-
Typhus 0 trials · 3 incl. sub-types
3 sub-types
- Scrub typhus 3 trials
- Endemic typhus 0 trials
- Epidemic louse-borne typhus 0 trials Sub-types →
-
Hantavirus pulmonary syndrome 2 trials
-
Relapsing fever 2 trials
2 sub-types
- Louse-borne relapsing fever 0 trials
- Tick-borne relapsing fever 0 trials
-
Oropouche fever 1 trial
-
Venezuelan equine encephalitis 1 trial
-
West Nile fever 1 trial
1 sub-type
- West-Nile encephalitis 1 trial Sub-types →
-
Zika virus congenital syndrome 1 trial
-
Lymphocytic choriomeningitis 1 trial
-
Tungiasis 1 trial
-
Spotted fever 0 trials · 1 incl. sub-types
11 sub-types
- Rocky mountain spotted fever 1 trial
- African tick-bite fever 0 trials
- Flinders island spotted fever 0 trials
- Japanese spotted fever 0 trials
- Queensland tick typhus 0 trials
- Rickettsia conorii infectious disease 0 trials Sub-types →
- Rickettsia helvetica spotted fever 0 trials
- Rickettsia parkeri spotted fever 0 trials
- Siberian tick typhus 0 trials
- Pseudotyphus of California 0 trials
- Rickettsialpox 0 trials
-
Alkhurma hemorrhagic fever 0 trials
-
Argentine hemorrhagic fever 0 trials
-
Bolivian hemorrhagic fever 0 trials
-
Colorado tick fever 0 trials
-
Murray valley encephalitis 0 trials
-
O'nyong'nyong fever 0 trials
-
Ross river fever 0 trials
-
Venezuelan hemorrhagic fever 0 trials
-
Whitewater Arroyo hemorrhagic fever 0 trials
-
Bacterial esophagitis 0 trials
-
Fungal esophagitis 0 trials
1 sub-type
- Esophageal candidiasis 0 trials
-
Phlebotomus fever 0 trials
-
Rat-bite fever 0 trials
2 sub-types
- Spirillary rat-bite fever 0 trials
- Streptobacillary rat-bite fever 0 trials
-
Trench fever 0 trials
-
Tularemia 0 trials
6 sub-types
- Gastrointestinal tularemia 0 trials
- Glandular tularemia 0 trials
- Oculoglandular tularemia 0 trials
- Pneumonic tularemia 0 trials
- Typhoidal tularemia 0 trials
- Ulceroglandular tularemia 0 trials
Most studied deeper sub-types
-
Ancient herb put to the test against hidden malaria
Cure Not yet recruitingResearchers in Gabon are testing whether a tea made from dried Artemisia annua leaves can clear malaria parasites in adults who carry the infection without feeling sick. The trial enrolls 20 semi-immune adults aged 18 to 45 who have low levels of Plasmodium falciparum in their bl…
Phase 1 • Sponsor: Centre de Recherche Médicale de Lambaréné • Aim: Cure
Last updated Sep 17, 2026 00:00 UTC
-
New malaria combo aims to stop relapses for good
Cure Not yet recruitingThis Phase 2b trial tests whether a new drug, SJ733, combined with tafenoquine can cure P. vivax malaria and prevent it from returning. About 104 adults with uncomplicated malaria will receive different schedules of SJ733 plus tafenoquine, or standard chloroquine plus tafenoquine…
Phase 2 • Sponsor: R. Kiplin Guy • Aim: Cure
Last updated Aug 01, 2026 00:00 UTC
-
New pill could cure parasitic skin disease in months
Cure Not yet recruitingThis study tests two doses of an experimental oral drug, LXE408, against a standard treatment (miltefosine) for localized cutaneous leishmaniasis, a parasitic skin disease. About 250 adults in the Americas will take the medicine for several weeks. The main goal is to see if the s…
Phase 2 • Sponsor: Drugs for Neglected Diseases • Aim: Cure
Last updated Jun 27, 2026 12:29 UTC
-
3-Day malaria cure could transform treatment
Cure Not yet recruitingThis study tests a shorter, higher-dose course of primaquine to cure vivax malaria and prevent it from coming back. Current treatments take too long, so a 3-day course could make it easier for patients to complete therapy. The trial involves over 1,000 people aged 5 and older wit…
Phase 3 • Sponsor: Menzies School of Health Research • Aim: Cure
Last updated Jun 27, 2026 11:00 UTC
-
Half-Dose malaria vaccine could double protection for millions
Vaccine Not yet recruitingThis study tests whether a half-dose of the R21/Matrix-M malaria vaccine is as effective as the full dose in 375 adults and adolescents aged 14 to 60. Participants will receive either the standard dose or a half-dose, and researchers will measure their immune response and safety.…
Phase 4 • Sponsor: University of Oxford • Aim: Vaccine
Last updated Aug 06, 2026 00:00 UTC
-
Can a single shot of a genetically weakened malaria parasite train the body to fight off the real thing?
Vaccine Not yet recruitingThis trial tests a new malaria vaccine, PfSPZ-LARC2, made from live but genetically weakened malaria parasites that stop developing in the liver and never reach the bloodstream. The goal is to see if a single dose can safely and effectively protect healthy adults in Burkina Faso …
Phase 1 • Sponsor: Sanaria Inc. • Aim: Vaccine
Last updated Aug 02, 2026 00:00 UTC
-
Could a second dose of dengue vaccine boost protection for kids?
Vaccine Not yet recruitingThis study tests whether a two-dose regimen of the Butantan-DV dengue vaccine, given nine months apart, produces a stronger immune response than a single dose in children and adolescents aged 2 to 17 who have never had dengue. The trial also checks that the vaccine made at a new …
Phase 3 • Sponsor: Butantan Institute • Aim: Vaccine
Last updated Jul 22, 2026 00:00 UTC
-
One shot, two protections? new trial combines dengue and chikungunya vaccines
Vaccine Not yet recruitingThis Phase 3 trial will test whether giving the dengue and chikungunya vaccines at the same time is as safe and effective as giving them separately. The study involves 900 healthy adults aged 18 to 59 who have never been exposed to either virus. Researchers will measure immune re…
Phase 3 • Sponsor: Butantan Institute • Aim: Vaccine
Last updated Jul 18, 2026 00:00 UTC
-
New chikungunya vaccine enters first human safety trial
Vaccine Not yet recruitingThis early-stage trial tests a new vaccine called PepGNP-ChikV, made from tiny synthetic particles, to see if it is safe and triggers an immune response against chikungunya virus. Forty healthy adults aged 18 to 60 will receive two doses 42 days apart. The study focuses on safety…
Early phase 1 • Sponsor: Gylden Pharma Ltd • Aim: Vaccine
Last updated Jun 27, 2026 12:24 UTC
-
New malaria vaccine candidate enters human trial in thailand
Vaccine Not yet recruitingThis phase II trial tests a new malaria vaccine called PvRII/Matrix-M in 36 healthy Thai adults aged 20-55. Half receive the vaccine, half a placebo. After three doses, 24 volunteers will be exposed to the malaria parasite in a controlled setting to see if the vaccine reduces inf…
Phase 2 • Sponsor: University of Oxford • Aim: Vaccine
Last updated Jun 27, 2026 12:00 UTC
-
New malaria vaccine trial aims to stop recurrent fever
Vaccine Not yet recruitingThis study tests an experimental vaccine called PvCS/Montanide ISA-51 to see if it can protect against P. vivax malaria, a major cause of recurrent fever and anemia. 72 healthy adults in Colombia will receive either the vaccine or a placebo, then be exposed to infected mosquitoes…
Phase 2 • Sponsor: Malaria Vaccine and Drug Development Center • Aim: Vaccine
Last updated Jun 27, 2026 09:00 UTC
-
New malaria vaccine vivaxin enters first human tests
Vaccine Not yet recruitingThis early-stage trial is testing a new vaccine called Vivaxin, designed to protect against malaria caused by the Plasmodium vivax parasite. Researchers will give the vaccine to 48 healthy adults who have never had malaria, to check if it is safe and whether it triggers an immune…
Phase 1 • Sponsor: Federal University of Minas Gerais • Aim: Vaccine
Last updated Jun 26, 2026 17:21 UTC
-
Can extra doses of an old drug reverse liver scarring?
Disease control Not yet recruitingThis trial tests whether giving praziquantel three times a year, instead of the standard once a year, can improve liver fibrosis (scarring) caused by schistosomiasis in people aged 15-40 in Uganda. Participants with liver fibrosis will be randomly assigned to one of two treatment…
Phase 2/3 • Sponsor: Rhode Island Hospital • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New hope for the tiniest malaria patients: a safer treatment for infants under 5 kg
Disease control Not yet recruitingThis study tests a specially formulated dispersible tablet, Coartem Baby, in infants weighing between 2 and 5 kg who have uncomplicated malaria. The goal is to see if the drug is safe and effectively clears symptoms like fever and chills. Twenty infants will receive the standard …
Phase 4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New malaria pill shows promise in early trial
Disease control Not yet recruitingThis phase 2 study tests a new antimalarial drug called GSK3772701 in 70 adults with uncomplicated P. falciparum malaria. Participants receive different doses for 1 to 3 days to see if it is safe and clears the parasite. The goal is to find a new treatment option that could work …
Phase 2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Laser boost for leishmaniasis treatment?
Disease control Not yet recruitingThis study tests whether adding a fractional CO₂ laser to standard Glucantime injections helps heal skin sores from leishmaniasis faster and with less scarring. About 150 adults will be randomly assigned to get either the injection alone or the injection plus laser. Researchers w…
Phase 2 • Sponsor: Combined military hospital Peshawar • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail aims to beat tough infection in HIV patients
Disease control Not yet recruitingThis trial tests whether adding a fluoroquinolone antibiotic to the standard three-drug treatment helps HIV patients with a serious bacterial infection called disseminated MAC. About 124 adults will be randomly assigned to get either the standard therapy or the four-drug combo fo…
Sponsor: Shanghai Public Health Clinical Center • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Massive dengue drug trial aims to stop deadly progression
Disease control Not yet recruitingThis large study tests several treatments in people hospitalized with moderate or severe dengue. The goal is to find safe, affordable drugs that prevent the disease from getting worse and help patients recover faster. Over 8,800 participants across multiple sites will be enrolled…
Phase 3 • Sponsor: Oxford University Clinical Research Unit, Vietnam • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New malaria cocktail aims to knock out relapsing p. vivax
Disease control Not yet recruitingThis study tests whether combining tafenoquine with different antimalarial drugs can better prevent P. vivax malaria from coming back. About 300 adults in Thailand with uncomplicated P. vivax infection will receive one of three drug pairs and be monitored for 6 months. The goal i…
Sponsor: Walter Reed Army Institute of Research (WRAIR) • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New study aims to safely treat breastfeeding moms for malaria
Disease control Not yet recruitingThis study looks at how much of the malaria drugs primaquine and tafenoquine pass to babies through breast milk. It involves 60 breastfeeding mothers in Papua New Guinea who recently gave birth. The goal is to find a safe way to treat and prevent relapses of vivax malaria in new …
Phase 2/3 • Sponsor: Curtin University • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Malaria drug combo under scrutiny: could tafenoquine interact?
Disease control Not yet recruitingThis study looks at whether a malaria drug called tafenoquine interacts with two other common malaria treatments (DHA-piperaquine and artesunate-pyronaridine) in adults with vivax malaria. About 507 participants will receive one of the combinations or a delayed treatment to compa…
Phase 4 • Sponsor: Menzies School of Health Research • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Major trial launches to find better treatments for Flesh-Eating parasite
Disease control Not yet recruitingThis Phase 3 trial in Ethiopia will compare four different drug regimens against the standard treatment for cutaneous leishmaniasis, a parasitic skin disease. 900 patients aged 4 to 65 will be hospitalized and treated for up to 28 days, with follow-up for 6 months. The goal is to…
Phase 3 • Sponsor: Institute of Tropical Medicine, Belgium • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New study eyes selexipag for neglected form of lung hypertension
Disease control Not yet recruitingThis study looks at how well the oral medication selexipag works over the long term for people with a specific type of lung hypertension caused by schistosomiasis (a parasitic infection). Researchers will compare patients who received selexipag as part of routine care to similar …
Sponsor: Caio Júlio César dos Santos Fernandes • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New hope for kids: shorter malaria treatment on the horizon
Disease control Not yet recruitingThis study will test the safety and effectiveness of a drug called tafenoquine in 60 children with vivax malaria in Papua New Guinea. Vivax malaria can hide in the liver and come back, so the goal is to find a treatment that clears the infection completely. The children will rece…
Phase 4 • Sponsor: Curtin University • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Could a gel heal parasite skin sores? new study begins
Disease control Not yet recruitingThis early study tests a gel made with the drug miltefosine for people with uncomplicated cutaneous leishmaniasis, a skin infection from a parasite. Fifteen adults will apply the gel to their sores daily for 28 days. The main goal is to see if the gel is safe and if it helps the …
Phase 1 • Sponsor: Universidad Industrial de Santander • Aim: Disease control
Last updated Jun 26, 2026 14:49 UTC
-
Could a new drug combo wipe out three parasitic diseases at once?
Disease control Not yet recruitingThis large study in Fiji tests whether a new combination of drugs (moxidectin plus two others) can safely treat three common parasitic infections: lymphatic filariasis, scabies, and strongyloidiasis. About 5,100 people will receive either the new combo or the standard treatment o…
Phase 3 • Sponsor: Medicines Development for Global Health • Aim: Disease control
Last updated Jun 26, 2026 14:32 UTC
-
Smart wristbands may spot malaria before symptoms strike
Diagnosis Not yet recruitingThis early-stage study tests whether wearable biosensors (like a wristband or earphones) can detect malaria infection before symptoms appear. 32 healthy adults will be exposed to the malaria parasite or a placebo in a controlled setting. Researchers will compare biosensor reading…
Phase 1 • Sponsor: University of Maryland, Baltimore • Aim: Diagnosis
Last updated Sep 11, 2026 00:00 UTC
-
New rapid tests aim to speed up ebola and lassa fever diagnosis
Diagnosis Not yet recruitingThis study evaluates two new diagnostic tests (FORTIFIEDx and DECIPHER) for detecting Ebola and Lassa viruses. Researchers will use stored blood and cheek swab samples from patients in Guinea to see how well these tests compare to the standard PCR method. The goal is to determine…
Sponsor: Institute of Tropical Medicine, Belgium • Aim: Diagnosis
Last updated Jul 04, 2026 00:00 UTC
-
AI app aims to help frontline workers diagnose neglected skin diseases
Diagnosis Not yet recruitingThis study tests whether a mobile app using artificial intelligence can help frontline health workers in sub-Saharan Africa better diagnose skin-related neglected tropical diseases, like leprosy and scabies. Researchers will collect images from dermatologists to train the AI, the…
Sponsor: Kenya Medical Research Institute • Aim: Diagnosis
Last updated Jun 27, 2026 12:04 UTC
-
Simple urine test could revolutionize schistosomiasis detection
Diagnosis Not yet recruitingThis study aims to develop a new urine test for schistosomiasis, a parasitic infection. Researchers will test a nanobody-based strip on 2500 participants, comparing it to the standard microscope method. If accurate, it could offer a quick, non-invasive diagnostic tool.
Sponsor: Pemba Ministry of Health Zanzibar • Aim: Diagnosis
Last updated Jun 27, 2026 12:03 UTC
-
New plague test could speed up diagnosis in remote congo
Diagnosis Not yet recruitingThis study will test a new rapid diagnostic test for plague in the Ituri province of DR Congo. Researchers will collect samples like blood, saliva, and bubo fluid from 300 people with suspected plague to see how well the new test works compared to standard lab methods. The goal i…
Sponsor: Institute of Tropical Medicine, Belgium • Aim: Diagnosis
Last updated Jun 27, 2026 12:01 UTC
-
New study aims to sharpen dengue diagnosis
Diagnosis Not yet recruitingThis study will collect blood samples from 200 people aged 12 and older who either have or do not have dengue. The goal is to use these samples to develop and improve diagnostic tests for dengue. Participants must have symptoms consistent with dengue and cannot have been vaccinat…
Sponsor: Abbott Rapid Dx • Aim: Diagnosis
Last updated Jun 27, 2026 07:52 UTC
-
School-Based malaria treatment could slash community infections
Prevention Not yet recruitingThis study tests whether giving malaria medicine to school-age children can lower malaria cases in the entire community. School children often carry the malaria parasite without symptoms and spread it to others. The trial will involve about 4,800 children in The Gambia and measur…
Phase 4 • Sponsor: University of California, San Francisco • Aim: Prevention
Last updated Sep 13, 2026 00:00 UTC
-
Can monthly malaria pills sharpen Children's minds?
Prevention Not yet recruitingThis trial tests whether giving schoolchildren in Kenya an antimalarial drug every month, instead of every three months, better protects their brain function and school performance. Researchers will enroll 1,500 children aged 6 to 10 from six primary schools. Half will receive mo…
Phase 3 • Sponsor: Indiana University • Aim: Prevention
Last updated Sep 03, 2026 00:00 UTC
-
A baby wrap that fights malaria? a new trial puts treated fabric to the test
Prevention Not yet recruitingThis trial tests whether baby wraps (called lesus) treated with long-lasting insecticide can protect young children from malaria. About 1,300 mothers and their infants (2-4 months old) will be randomly assigned to receive a wrap treated with permethrin, etofenprox, or an untreate…
Sponsor: University of North Carolina, Chapel Hill • Aim: Prevention
Last updated Aug 21, 2026 00:00 UTC
-
Can a pill make your blood deadly to malaria mosquitoes?
Prevention Not yet recruitingThis trial tests whether a single oral dose of lotilaner, a drug currently used in animals, can make human blood lethal to Anopheles gambiae mosquitoes, the main carriers of malaria. Healthy adults in Mali will receive either a low or high dose of lotilaner or a placebo, with or …
Phase 1 • Sponsor: Medicines for Malaria Venture • Aim: Prevention
Last updated Aug 13, 2026 00:00 UTC
-
Could a simple device help curb malaria in children?
Prevention Not yet recruitingThis study tests whether a device called the Guardian spatial emanator, which releases mosquito-repelling ingredients into the air, can be effectively added to an existing program that distributes antibiotics to children in Niger. The goal is to see if this integrated approach ca…
Sponsor: University of California, San Francisco • Aim: Prevention
Last updated Jul 24, 2026 00:00 UTC
-
New malaria antibody enters first human safety tests
Prevention Not yet recruitingThis early-stage study tests a new antibody drug (GSK4425689A) designed to prevent malaria. Researchers will give the drug to 40 healthy adults either through an IV or a shot under the skin to check for side effects and how the body processes it. The goal is to see if it is safe …
Phase 1 • Sponsor: GlaxoSmithKline • Aim: Prevention
Last updated Jun 27, 2026 13:06 UTC
-
One shot to stop malaria? new injection tested in rwanda
Prevention Not yet recruitingThis study tests a new long-acting injection called MMV371 to see if it is safe and can prevent malaria. About 80 healthy people aged 12 to 50 in Rwanda will get either the study drug or a placebo. Researchers will check if the injection protects against malaria and monitor side …
Phase 1 • Sponsor: Medicines for Malaria Venture • Aim: Prevention
Last updated Jun 27, 2026 12:23 UTC
-
Could a simple device keep mosquitoes away better than spraying?
Prevention Not yet recruitingThis study tests new devices called LASER that release a chemical to repel mosquitoes, comparing them to indoor insecticide spraying and standard prevention (bed nets, vaccines). About 22,800 people in 69 Kenyan villages will take part over two years. Researchers will check malar…
Sponsor: Liverpool School of Tropical Medicine • Aim: Prevention
Last updated Jun 27, 2026 09:01 UTC
-
New antibody shot could shield against Tick-Borne brain virus
Prevention Not yet recruitingThis early-stage study tests a lab-made antibody called TBE025 in 18 healthy adults aged 18 to 55. The goal is to see if it is safe and how the body processes it when given through a vein. Participants receive one dose and are closely monitored for side effects. This research hel…
Phase 1 • Sponsor: Giuseppe Pantaleo • Aim: Prevention
Last updated Jun 27, 2026 09:00 UTC
-
New combo strategy aims to slash malaria in kids
Prevention Not yet recruitingThis study in Uganda will test whether giving children both the R21 malaria vaccine and two different malaria prevention medicines works better than the vaccine alone. About 1,290 children will take part. The goal is to see if the combination can reduce malaria cases more effecti…
Phase 4 • Sponsor: Stanford University • Aim: Prevention
Last updated Jun 27, 2026 08:08 UTC
-
Could a malaria drug ease lingering lyme symptoms?
Symptom relief Not yet recruitingThis study tests whether adding hydroxychloroquine (a malaria drug) to standard doxycycline treatment can reduce long-term complaints in adults with Lyme disease. Fifty participants will take either hydroxychloroquine or a placebo twice daily for 28 days, with follow-up visits ov…
Phase 4 • Sponsor: Radboud University Medical Center • Aim: Symptom relief
Last updated Aug 29, 2026 00:00 UTC
-
Exercise program aims to restore strength after dengue and chikungunya
Symptom relief Not yet recruitingThis study tests whether a 20-session exercise program can improve muscle strength, reduce fatigue, and help with balance in people who had dengue or chikungunya in the last five years. Fifty-four adults will do supervised aerobic, strength, and breathing exercises twice a week. …
Sponsor: Universidade do Estado do Pará • Aim: Symptom relief
Last updated Jun 27, 2026 12:38 UTC
-
New hope for Tick-Bite survivors: mast cell drugs aim to ease lingering symptoms
Symptom relief Not yet recruitingThis study tests whether medications that calm mast cells (ketotifen and cromolyn) can safely reduce persistent symptoms like fatigue, pain, and brain fog in people who had a tick-borne illness. Fifty adults aged 21-65 will receive either one of these drugs or a standard antihist…
Phase 2 • Sponsor: University of North Carolina, Chapel Hill • Aim: Symptom relief
Last updated Jun 27, 2026 12:07 UTC
-
Prison walls may not stop Animal-Borne diseases
Knowledge-focused Not yet recruitingResearchers are measuring how often five animal-borne infections appear among inmates at the French Guiana Correctional Facility. The study follows newly arrived adults for up to 12 months, testing for Q fever, leptospirosis, Chagas disease, histoplasmosis, and toxoplasmosis. The…
Sponsor: Centre Hospitalier de Cayenne • Aim: Knowledge-focused
Last updated Sep 11, 2026 00:00 UTC
-
Can detailed tracking of dengue patients sharpen the next generation of clinical trials?
Knowledge-focused Not yet recruitingThis observational study follows 235 people hospitalised with dengue in Vietnam to map how the illness unfolds, especially the leaking of blood vessels that can lead to severe disease. Researchers will collect routine clinical data, blood samples, and ultrasound scans during the …
Sponsor: Liverpool School of Tropical Medicine • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
Malaria drug combo under microscope: safety first
Knowledge-focused Not yet recruitingThis early-stage trial will give 24 healthy adults three different malaria drugs—piperaquine, pyronaridine, and artesunate—alone and together to see how they interact. Researchers will measure drug levels in the blood and watch for side effects. The goal is to learn about safety …
Phase 1 • Sponsor: University of Oxford • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
Heart-Lung connection may explain survival advantage in Parasite-Linked hypertension
Knowledge-focused Not yet recruitingThis study looks at how well the right side of the heart works with the lungs in people who have high blood pressure in their lung arteries caused by schistosomiasis, a parasitic infection common in parts of Africa and South America. Researchers will use echocardiography to measu…
Sponsor: Sohag University • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
Immune cell tracking could sharpen lyme disease diagnosis
Knowledge-focused Not yet recruitingThis study explores a new way to diagnose Lyme disease by measuring immune cell responses to the bacteria. Researchers use a technique called flow cytometry to analyze T-cells from patients with a late-stage form of Lyme disease. The goal is to see if this method can tell active …
Sponsor: University Hospital, Strasbourg, France • Aim: Knowledge-focused
Last updated Jul 16, 2026 00:00 UTC
-
Chagas drug safety in pregnancy under scrutiny in new 10-year study
Knowledge-focused Not yet recruitingThis study follows 50 pregnant women with Chagas disease who take or have taken nifurtimox, to see if the drug causes harm to the baby or mother. Researchers will track birth defects, pregnancy outcomes, and infant health up to 12 months old. The goal is to collect safety data, n…
Sponsor: Bayer • Aim: Knowledge-focused
Last updated Jul 08, 2026 00:00 UTC
-
Gene study aims to sharpen malaria pill dosing
Knowledge-focused Not yet recruitingThis study looks at how different genetic makeups affect the way healthy adults process the malaria prevention drug tafenoquine (ARAKODA). Researchers will measure drug levels in blood and urine over time, along with safety checks. The goal is to better understand how to dose the…
Early phase 1 • Sponsor: State University of New York - Upstate Medical University • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:04 UTC
-
Egyptian schistosomiasis study launches to map disease hotspots
Knowledge-focused Not yet recruitingThis study will measure how many people in Assiut Governorate, Egypt, have schistosomiasis, a parasitic disease. Researchers will test urine and stool samples from 359 participants and ask about risk factors. The goal is to better understand the current burden of the disease in t…
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Massive french study to track virus effects on pregnant women and kids for 7 years
Knowledge-focused Not yet recruitingThis study will follow 5,160 pregnant women in France who have HIV, hepatitis B, hepatitis C, or an arbovirus infection (like Zika or dengue), along with their children, for up to 7 years. Researchers want to learn how these viruses and their treatments affect pregnancy, the moth…
Sponsor: ANRS, Emerging Infectious Diseases • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC
-
Scientists investigate mysterious lung infection in south china
Knowledge-focused Not yet recruitingThis study looks at a lung infection called NTM lung disease in South China. Researchers will review medical records of about 1,500 patients and collect samples from around 100 current patients to learn how the immune system reacts. The goal is to help doctors diagnose and manage…
Sponsor: Eighth Affiliated Hospital, Sun Yat-sen University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Hidden Tick-Borne arthritis under investigation in denmark
Knowledge-focused Not yet recruitingThis study aims to find out how common Borrelia arthritis is in Denmark and how it affects patients. Researchers will test blood and joint fluid from 350 adults with joint swelling to look for Borrelia bacteria. Participants will also answer questions about symptoms and tick expo…
Sponsor: Fredrikke Christie Knudtzen • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC
-
Iron boost may make vaccines more effective in kenyan infants
Knowledge-focused Not yet recruitingThis study looks at whether giving iron to babies with low iron helps their bodies respond better to malaria and measles vaccines. About 324 infants in Kenya will take part. The goal is to see if treating iron deficiency can improve how well the vaccines protect them.
Sponsor: Nicole Stoffel • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
Rare infection study aims to save lives by uncovering hidden clues
Knowledge-focused Not yet recruitingThis study looks back at 400 adults in France who had a rare but serious blood vessel infection caused by the bacteria Coxiella burnetii. The goal is to learn why some patients die within two years and how to diagnose the infection faster. Researchers will review medical records …
Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
New study aims to bring mental health support to people with neglected skin diseases in ghana
Knowledge-focused Not yet recruitingThis study will test a new way to care for people in Ghana who have both a neglected tropical skin disease (like leprosy or Buruli ulcer) and mental health challenges like depression or anxiety. Researchers will work with 200 affected adults and local health workers to create a G…
Sponsor: Liverpool School of Tropical Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
Silent threat: study to uncover hidden spread of brain infection in cambodian kids
Knowledge-focused Not yet recruitingThis study will follow 4,000 children in Cambodia to understand how common Japanese Encephalitis (JE) is and how often it spreads without symptoms. Researchers will compare healthy children with those hospitalized for fever and brain-related symptoms. The goal is to measure the t…
Sponsor: ANRS, Emerging Infectious Diseases • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:48 UTC